Home  |  Site Map  |  Contact Us  |  
Search

 

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing Horizant® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis. Regnite is being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.

For more information, please click here


For more information, please click here

Tue, 22 Jul 2014
XenoPort to Release Second Quarter Financial Results on August 6, 2014

Mon, 23 Jun 2014
XenoPort Announces Initiation of a Phase 2 Clinical Trial of XP23829 in Patients With Psoriasis

 

Q2 2014 XenoPort, Inc. Earnings Conference Call
Aug 6, 2014 at 5:00 PM ET

2014 Wells Fargo Healthcare Conference
Jun 18, 2014 at 11:25 AM PT

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis.

Explore the XenoPort Pipeline >